Concepedia

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous<i>in vivo</i>delivery of tyrosine kinase inhibitors and kinase activity biosensors

Robin Bofinger, Gregory Weitsman, Rachel Evans, Matthias Glaser, Kerstin Sander, Helen Allan, Daniel Hochhauser, Tammy L. Kalber, Erik Årstad, Tony Ng,

Nanoscale · 2021 · 13 citations · 53 references

DOIFull text

Open access

Concepts

Abstract

We report the development of targeted theragnostic lipid/peptide/DNA lipopolyplexes for delivery of both a tyrosine kinase inhibitor, and plasmid DNA coding for a biosensor. These are used to quantify EGFR inhibition in cancer cell lines in vivo .

References

53

Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

Philip L. Felgner, Thomas R. Gadek, Mai Marie Holm et al. · Proceedings of the National Academy of Sciences · 1987 · 5K citations · Full text

, , +15

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

, , +16

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Ki Y. Chung, Jinru Shia, Nancy E. Kemeny et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

, , +15

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Fortunato Ciardiello, Giampaolo Tortora · PubMed · 2001 · 988 citations

, , +17

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Lisa A. Carey, Hope S. Rugo, P. Kelly Marcom et al. · Journal of Clinical Oncology · 2012 · 493 citations · Full text

, , +17